Triple-negative breast cancer trials in Spain
33 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Barcelona, Bilbao, Jaén, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Salamanca, Santiago de Compostela, Sevilla, Valencia
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 1Taking peopleA Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Where
- Logrono, Madrid, Valencia
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00 - Phase 1/2Taking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Barcelona, Madrid, Sevilla
- Age
- 18 years and over
- People
- 1,132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Sevilla, Valencia
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - Phase 1Taking peopleA Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- A Coruña, Badalona, Barakaldo, Barcelona, Cáceres, Castello De La Plana, Córdoba, Donostia, Elche, Fuenlabrada, Galdakao, Granada, Jaén, La Laguna, León, Lleida, Madrid, Málaga, Manresa, Murcia, Pamplona, Reus, Sabadell, Santander, Sevilla, Toledo, Valencia, Valladolid, Zaragoza
- Age
- 18 years and over
- People
- 1,514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - Phase 1Taking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Barcelona, Madrid, Valencia
- Age
- 18 years and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- L'Hospitalet de Llobregat, Madrid, Sevilla
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 1/2Taking peopleTreatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
- Where
- Barcelona, Madrid, Pamplona
- Age
- 18 years and over
- People
- 20
- Run by
- Fundacio Clinic Barcelona
See details and how to joinNCT05451784 · EU 2024-511915-21-01 - Phase 3Taking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Badajoz, Barcelona, Córdoba, Madrid, Murcia, Pamplona, Sabadell, Valencia
- Age
- 18 years and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - Phase 1Not yet taking people in SpainA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - Phase 1Taking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona, Zaragoza
- Age
- 18 years and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - Phase 2Taking peopleA clinical study of patritumab deruxtecan in people with breast cancer
- Where
- Badalona, Barcelona, Córdoba, Madrid, Málaga, Valencia
- Age
- 18 years and over
- People
- 10
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-514376-40-00 · EU 2024-514376-40-00 - Phase 1/2Taking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Barcelona, Madrid, Rioja, Valencia
- Age
- 12 years and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - Phase 1Taking peopleA Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Where
- Barcelona, Logroño, Madrid
- Age
- 18 years and over
- People
- 124 worldwide
- Run by
- Pliant Therapeutics, Inc.
See details and how to joinNCT06270706 - Phase 3Taking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander
- Age
- 18 years and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - Phase 3Taking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- Where
- Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-503675-24-00 · EU 2023-503675-24-00 - Phase 1/2Taking peopleA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Where
- Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville, Valencia
- Age
- 18 years and over
- People
- 416 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06618287 - Phase 1Taking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Barcelona, Madrid, Piqueras, Seville
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - Phase 1Taking peopleA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Barcelona, L'Hospitalet de Llobregat
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00 - Phase 1/2Taking peopleFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06657222 · EU 2025-522517-35-00 - Phase 1/2Taking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Badalona, Barcelona, Madrid, Málaga, Pamplona
- Age
- 18 years and over
- People
- 1,109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - Phase 2/3Taking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- A Coruña, Barcelona, Donostia, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - Phase 1Taking peoplePhase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Where
- Barcelona, Madrid
- Age
- 18 years to 100 years
- People
- 162 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06562192